REFI · CIK 1867949
What Chicago Atlantic Real Estate Finance, Inc. told the SEC could break it.
Chicago Atlantic's risks all trace to a single sector: its entire loan portfolio is lent to cannabis-industry borrowers — state-licensed cultivators, processors, retailers and ancillary businesses in the U.S. and Canada — so any cannabis-sector downturn would hit the whole book. That exposure is also concentrated by jurisdiction, with Illinois borrowers about 19% and Ohio about 15% of the portfolio at year-end 2025, tying it to those states' cannabis regimes. Overhanging it all is federal illegality: cannabis remains a Schedule I drug, and although HHS has recommended reclassification to Schedule III, DEA approval and rulemaking are uncertain, leaving its borrowers and business exposed to federal enforcement and banking constraints.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- Loan portfolio entirely to cannabis-industry borrowersmedium
The entire loan book is concentrated in the cannabis industry — state-licensed cultivators, processors, distributors, retailers, and ancillary businesses in the U.S. and Canada — so a cannabis-sector downturn would hit the whole portfolio.
“state-licensed cannabis cultivators, processors, distributors, retailers, vertically-integrated cannabis firms, non-plant touching manufacturers, suppliers, and service providers to such industries, and other businesses ancillary thereto, located in the U.S. and Canada.”
SEC filing →As of 2026
Geographic concentration
- Borrower jurisdiction concentration (Illinois 19%, Ohio 15%)medium
Geographic concentration is a key credit-quality indicator; at Dec 31, 2025 borrowers in Illinois were ~19% and Ohio ~15% of the loan portfolio, concentrating exposure to those states' cannabis regimes.
“Geographic concentration of our loans held for investment is also a significant credit quality indicator.”
SEC filing →As of 2026
Regulatory & policy
- Federal illegality of cannabis (Schedule I; DEA rescheduling pending)low
Cannabis remains federally illegal as a Schedule I drug; HHS has recommended reclassification to Schedule III but DEA approval and rulemaking are uncertain, leaving the lender's borrowers and business exposed to federal enforcement and banking constraints.
“the U.S. Department of Health and Human Services (“HHS”) recommended to the DEA that cannabis be reclassified from a Schedule I drug to a Schedule III drug under the CSA.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch